NanoVibronix Announces Distribution Agreement With Mano Equestrian Services (PTE) LTD in Singapore for Equine PainShield(R)

NanoVibronix Announces Distribution Agreement With Mano Equestrian Services (PTE) LTD in Singapore for Equine PainShield(R)

ELMSFORD, NY--(Marketwired - September 28, 2016) - NanoVibronix, Inc, (OTCQB: NAOV),a medical device company, today announced a distribution agreement with Mano Equestrian Services (PTE) LTD ("Mano") to market and distribute Equine PainShield® in Singapore. Mano's distribution network covers Malaysia, India, Indonesia, and all of the Arab countries. There are about 400,000 race and show horses throughout the world, a large number of which are in Mano's territory. In addition, Nanovibronix is exhibiting Equine PainShield® at the American Association of Equine Practitioners ("AAEP") meeting in Orlando, Florida on December 3-7, 2016. The AAEP is the largest race and show horse provider meeting in the U.S.

Nanovibronix's Equine PainShield® wearable ultrasound treatment for race and show horses treats suspensory injuries, tendonitis, ligament lesions, bone fractures, inflamed joints, osteoarthritis, and sore muscles. Suspensory ligament injuries are a common cause of lameness in horses. Current practices to heal common injuries normally take between 8 to 12 weeks which can be costly to race and show horse owners. Equine Paineshield® with its wearable ultrasound, in conjunction with other standard treatments, can reduce the healing time to 2 weeks.

William Stern, PhD Chief Executive Officer of NanoVibronix, stated, "After successfully treating equine athletes in Singapore with the Equine Painshield®, Mano decided to distribute our product. This is a validation of our product which reduces pain and healing time to two weeks, allowing equine race and show owners to reduce costs and downtime."

About NanoVibronix
NanoVibronix Inc. is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications. The devices accelerate wound healing and provide pain relief. The devices can also be administered at home, without the assistance of medical professionals. The company's products include PainShield® and WoundShield™, which both have CE Mark. The PainShield™ also has FDA clearance. NanoVibronix's catheter based products include the UroShield™ and NG-Shield™ that are both CE Marked. Additional information about the company is available at: www.nanovibronix.com.

SAFE HARBOR STATEMENT: This release contains certain statements that are, or may be deemed to be, forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934, and are made in reliance upon the protections provided by such Acts for forward-looking statements. We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form SEC filings.

Investor Relations Contacts:
Rodd Leeds or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020